Transitional cell carcinoma – Diagnostics

Go back

Transitional cell carcinoma diagnostics involves a series of tests that help doctors identify cancer in the urinary system. Early detection often makes treatment simpler and more effective, though the journey from first symptoms to confirmed diagnosis requires careful examination and specialized procedures.

Introduction: When to Seek Diagnostics

If you notice blood in your urine, you should contact a healthcare provider right away. This is usually the first noticeable sign of transitional cell carcinoma, though symptoms may not show up immediately in the early stages. Blood in the urine, medically called hematuria, appears when cancer affects the lining of your bladder, kidney, or the tubes connecting them.[1]

You should also seek medical attention if you experience painful or frequent urination, persistent lower back pain, extreme fatigue, or unexplained weight loss. Sometimes you might feel a lump or mass in your kidney area, which is the space on your side and back between your ribs and hips. Even if these symptoms come and go, it’s important not to ignore them.[1]

Adults over age 65 are more commonly affected by this cancer, and men develop it more frequently than women. If you have a history of bladder cancer, you face an increased risk of developing transitional cell carcinoma in your renal pelvis or ureters. Smokers and people who work with certain industrial chemicals also have higher risk, so they should be especially alert to any urinary symptoms.[1]

⚠️ Important
Because transitional cells line many different parts of your urinary tract, you can sometimes develop tumors in more than one place. If you have transitional cell carcinoma in your bladder, your doctor should also check for tumors in other parts of your urinary tract system.[3]

Classic Diagnostic Methods

Healthcare providers use several tests to diagnose bladder and kidney cancers, including transitional cell carcinoma. The diagnostic process typically begins with simpler tests and moves to more detailed examinations if needed.[1]

Urine Tests

Your doctor will start with a urinalysis on a urine sample. This test looks for abnormalities such as blood, protein, sugar, and other substances that shouldn’t be there. The laboratory checks the physical appearance of your urine and examines it under a microscope to detect any unusual cells.[8]

A more specialized test called urine cytology examines your urine sample specifically for cancer cells. When cancer affects the walls of your bladder or kidney, abnormal cells can slough off and be released into your urine. A laboratory technician looks at these cells under a microscope to identify any that appear cancerous.[1]

Imaging Tests

Imaging studies help doctors see tumors inside your body without surgery. You may need a CT scan (computed tomography scan), which provides a detailed, three-dimensional view of your urinary tract. This scan can determine if any masses or tumors exist in the bladder, kidneys, or ureters. The CT scan uses X-rays taken from different angles and combines them into cross-sectional images.[3]

An MRI (magnetic resonance imaging) scan uses magnets and radio waves instead of radiation to create detailed pictures of soft tissues in your body. Your doctor might also order a PET scan or an ultrasound. An ultrasound uses sound waves to create real-time images of your internal organs.[1]

A specialized imaging test called an intravenous pyelogram (IVP) uses a contrast dye that travels through your bloodstream to your kidneys, ureters, and bladder. The dye makes blockages or abnormal areas stand out clearly on an X-ray image, helping doctors identify problems in your urinary system.[1]

Scope Tests

Your provider may use a scope, which is a thin tube with a light and lens on the end, to look directly inside your bladder, kidneys, or ureters. During a cystoscopy, the doctor inserts a scope through your urethra (where you urinate) to examine the inside of your bladder. This procedure allows them to see abnormal areas directly.[1]

A ureteroscopy lets doctors look inside your ureter and renal pelvis for anything that doesn’t appear normal. The ureteroscope is a long, thin tube with a light that can navigate through your urinary system. During this procedure, your doctor can take tissue samples to check for signs of disease.[3]

These scope procedures allow doctors not only to see suspicious areas but also to take small tissue samples, called biopsies. A biopsy is when your doctor removes a small piece of tissue to examine it under a microscope for cancer cells. This is often the most definitive way to confirm a cancer diagnosis.[1]

Physical Examination and Medical History

Your doctor will perform a physical exam to look for any signs of disease. They will also take a detailed health history to learn about any past illnesses, your health habits, and risk factors like smoking or chemical exposure. This information helps them understand your overall health and determine which tests are most appropriate for you.[3]

⚠️ Important
Even if ureteroscopy and other scope procedures are successfully performed, accurately assessing how deeply the cancer has invaded the tissue can be difficult. Additional tests may be needed before doctors can recommend the best treatment approach.[15]

Diagnostics for Clinical Trial Qualification

When patients are being considered for clinical trials, additional diagnostic tests and assessments are typically required. Clinical trials have specific entry criteria, and doctors need detailed information about your cancer to determine if you qualify.[2]

Staging Tests

After transitional cell cancer has been diagnosed, doctors perform tests to find out if cancer cells have spread within the renal pelvis and ureter or to other parts of your body. This process is called staging. The stage of your cancer helps determine which clinical trials might be appropriate for you.[2]

Staging typically involves imaging tests of your chest, abdomen, and pelvis. A CT scan of your chest helps check whether the cancer has spread to your lungs. Additional scans of your abdomen look for spread to nearby lymph nodes or other organs.[5]

Grade Assessment

The grade of your cancer describes how abnormal the cancer cells look under a microscope. Transitional cell carcinoma is generally graded as low grade or high grade. Low-grade tumors have cells that look more like normal cells and tend to grow slowly. High-grade tumors have cells that look very abnormal and tend to grow and spread more quickly.[10]

Clinical trials often specify which grades of cancer they will accept. High-grade cancers are more aggressive, so trials testing new aggressive treatments might focus on these patients. Low-grade cancers might be included in trials testing less intensive approaches.[3]

Performance Status

Your overall health and ability to perform daily activities, called your performance status, is another important factor for clinical trial eligibility. Doctors assess whether you are strong enough to handle the trial treatment and whether you can attend all required appointments and follow the study protocol.[2]

Kidney Function Tests

Because transitional cell carcinoma affects the urinary system, tests that measure how well your kidneys are working are especially important. Blood tests can check your kidney function by measuring waste products that your kidneys should be filtering out. If one kidney is affected by cancer, your other kidney needs to be healthy enough to take over the work.[5]

Biomarker Testing

Some clinical trials require testing for specific biological markers, or biomarkers, in your tumor tissue. These are molecules or genetic changes in cancer cells that can predict how the cancer will behave or how it might respond to certain treatments. For example, some trials look for mutations in specific genes or for proteins on the surface of cancer cells.[4]

To perform biomarker testing, doctors need a tissue sample from your tumor, usually obtained through a biopsy. The tissue is sent to a specialized laboratory where technicians analyze the genetic makeup of the cancer cells and check for the presence of specific markers.[4]

Comprehensive Assessment

Clinical trials typically require a comprehensive assessment of your medical history, including all previous treatments, other health conditions you have, and medications you take. Some trials exclude patients who have received certain treatments before, while others specifically look for patients whose cancer has come back after initial treatment.[2]

The depth of infiltration into or through the wall of the urinary tract is a major prognostic factor and often determines trial eligibility. Superficial tumors that haven’t invaded deeply are likely to be well differentiated, while tumors that have infiltrated through the wall are likely to be poorly differentiated and more aggressive.[16]

Prognosis and Survival Rate

Prognosis

The outlook for patients with transitional cell carcinoma depends heavily on how far the cancer has spread at the time of diagnosis. Caught early, these cancers are easily treatable, though they often come back even after successful treatment. The major prognostic factor is the depth of infiltration into or through the wall of the urinary tract. Tumors that remain superficial and confined to the lining have a much better outlook than those that have grown deeply into the tissue.[1]

Most superficial tumors are likely to be well differentiated, meaning the cancer cells look more like normal cells. In contrast, tumors that have infiltrated through the wall are likely to be poorly differentiated, with cells that look very abnormal. The grade of the tumor also affects prognosis, with high-grade tumors being more aggressive than low-grade ones.[16]

Patients with a history of upper tract transitional cell cancer face a risk of developing new cancers. The incidence of cancers appearing in the opposite kidney or ureter ranges from two to four percent. More significantly, between thirty and fifty percent of patients develop bladder cancer after having upper tract transitional cell cancer. When the upper tract involvement is diffuse, affecting both the renal pelvis and ureter, the likelihood of subsequent bladder cancer increases to seventy-five percent.[16]

Survival Rate

Transitional cell cancers are curable in more than ninety percent of patients if they are superficial and confined to the renal pelvis or ureter. Patients with deeply invasive tumors that are still confined to the renal pelvis or ureter have a ten to fifteen percent likelihood of cure. Unfortunately, patients with tumors that have penetrated through the wall of the urinary tract or have spread to distant parts of the body usually cannot be cured with currently available forms of treatment.[16]

These statistics highlight the importance of early detection. When cancer is caught before it invades deeply or spreads to other organs, the chances of successful treatment and long-term survival are much higher. However, even after successful treatment, patients need ongoing monitoring because of the high risk that the cancer will return or develop in other parts of the urinary tract.[1]

Ongoing Clinical Trials on Transitional cell carcinoma

  • Study on PET Imaging with Fianlimab and Cemiplimab for Patients with Advanced Solid Tumors, with or without Platinum-Based Chemotherapy

    Recruiting

    1 1 1
    Investigated drugs:
    The Netherlands
  • Study of drug combination with gemcitabine, cisplatin, carboplatin and avelumab in patients with advanced urothelial cancer to evaluate response to platinum-based chemotherapy

    Recruiting

    1 1 1 1
    Investigated diseases:
    Italy
  • Study on Chemo-Immunotherapy with Avelumab for Patients with Locally Advanced Urothelial Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands
  • Study of TYRA-300 in Adults with Low Grade Upper Tract Urothelial Carcinoma to Assess Efficacy and Safety

    Not yet recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria France Spain
  • Safety and efficacy study of nadofaragene firadenovec administered to the renal pelvis in adults with low-grade upper tract urothelial carcinoma

    Not yet recruiting

    1 1
    Investigated diseases:
    France The Netherlands Spain
  • Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Spain
  • Study on Pembrolizumab and Cyclophosphamide for Patients with Metastatic Urothelial Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Austria Belgium Bulgaria Czechia Denmark France +12
  • Study of Atezolizumab Treatment Before Surgery in Patients with Bladder Cancer or Upper Urinary Tract Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Spain
  • Study of Durvalumab and Tremelimumab for Patients with Advanced Unresectable Urothelial Cancer

    Not recruiting

    1 1 1 1
    Greece Spain

References

https://my.clevelandclinic.org/health/diseases/6239-transitional-cell-cancer

https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq

https://www.webmd.com/cancer/transitional-cell-cancer

https://en.wikipedia.org/wiki/Transitional_cell_carcinoma

https://www.yalemedicine.org/conditions/transitional-cell-cancer-of-the-renal-pelvis-and-ureter

https://www.mayoclinic.org/diseases-conditions/bladder-cancer/symptoms-causes/syc-20356104

https://www.cancerresearchuk.org/about-cancer/upper-urinary-tract-urothelial-cancer

https://www.ebsco.com/research-starters/health-and-medicine/transitional-cell-carcinomas

https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq

https://www.mayoclinic.org/diseases-conditions/bladder-cancer/diagnosis-treatment/drc-20356109

https://www.ncbi.nlm.nih.gov/books/NBK66044/

https://emedicine.medscape.com/article/281484-treatment

https://www.yalemedicine.org/conditions/transitional-cell-cancer-of-the-renal-pelvis-and-ureter

https://my.clevelandclinic.org/health/diseases/6239-transitional-cell-cancer

https://www.cancer.gov/types/kidney/hp/transitional-cell-treatment-pdq

https://www.ncbi.nlm.nih.gov/books/NBK66010/

https://www.webmd.com/cancer/transitional-cell-cancer

https://my.clevelandclinic.org/health/diseases/6239-transitional-cell-cancer

https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq

https://www.cxbladder.com/row/blog/managing-life-after-bladder-cancer/

https://www.cancer.org/cancer/types/bladder-cancer/after-treatment/follow-up.html

https://thepatientstory.com/uc-san-francisco/kevin-r/

https://www.regionalcancercare.org/cancer-types/transitional-cell-carcinoma/

https://www.cancer.org.au/cancer-information/types-of-cancer/rare-cancers/upper-tract-urothelial-cancer

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

FAQ

What is the most common first symptom of transitional cell carcinoma?

Blood in your urine (hematuria) is usually the first noticeable sign. The blood may be visible to the naked eye or only detectable under a microscope. You should contact a healthcare provider if you notice bloody urine, even if the bleeding stops on its own.[1]

Is a biopsy always necessary to diagnose transitional cell carcinoma?

While urine tests and imaging can strongly suggest cancer, a biopsy is often the most definitive way to confirm the diagnosis. During scope procedures like cystoscopy or ureteroscopy, doctors can take small tissue samples and examine them under a microscope to look for cancer cells.[1]

Why do I need so many different tests?

Different tests provide different types of information. Urine tests can detect abnormal cells, imaging tests show where tumors are located and how large they are, and scope procedures allow doctors to see suspicious areas directly and take tissue samples. Together, these tests give your doctor a complete picture of your condition.[1]

How accurate are diagnostic tests at determining how deep the cancer has spread?

Even with advanced scope procedures like ureteroscopy, accurately assessing the depth of cancer invasion can be difficult. This is why multiple tests are often needed before doctors can confidently determine the stage of your cancer and recommend the best treatment approach.[15]

If I had bladder cancer before, do I need different diagnostic tests?

Having a history of bladder cancer increases your risk of transitional cell carcinoma in your renal pelvis and ureters. Your doctor will likely check your entire urinary tract, not just your bladder, because transitional cells line all of these areas and cancer can develop in multiple locations.[1]

🎯 Key Takeaways

  • Blood in urine is the most important warning sign and should never be ignored, even if it disappears on its own
  • Superficial transitional cell cancers confined to the urinary tract lining are curable in more than ninety percent of cases
  • Transitional cells are unique because they can stretch and shrink, which is why they line expandable organs like the bladder
  • Between thirty and fifty percent of patients develop bladder cancer after upper tract transitional cell cancer, requiring ongoing monitoring
  • Multiple diagnostic tests are necessary because each provides different information about the location, size, and invasiveness of the cancer
  • Clinical trial eligibility depends on detailed information about your cancer’s stage, grade, and specific biological markers
  • Accurately determining how deeply cancer has invaded tissue remains challenging even with advanced scope procedures
  • People over sixty-five, men, smokers, and those with bladder cancer history face higher risk and should be especially alert to symptoms